Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study
ConclusionThese prognostic scores are useful for identifying patients with mCRC who will obtain survival benefits from these drugs.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research